Detalhe da pesquisa
1.
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
N Engl J Med
; 386(12): 1132-1142, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35179323
2.
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.
Oncologist
; 29(3): 235-243, 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37812679
3.
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.
Prostate
; 83(14): 1351-1357, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37424145
4.
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
Prostate
; 83(3): 227-236, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36382533
5.
Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database.
Br J Cancer
; 129(11): 1759-1765, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37777577
6.
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med
; 382(23): 2197-2206, 2020 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469184
7.
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
N Engl J Med
; 383(13): 1218-1230, 2020 09 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-32945632
8.
Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.
J Urol
; 209(3): 532-539, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36756959
9.
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).
BMC Cancer
; 23(1): 781, 2023 Aug 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37608258
10.
Plain language summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide?
Future Oncol
; 19(29): 1953-1960, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37585665
11.
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.
Br J Cancer
; 126(3): 430-439, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35046520
12.
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 398(10295): 131-142, 2021 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34246347
13.
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
N Engl J Med
; 381(26): 2506-2518, 2019 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31566937
14.
Application of artificial intelligence to overcome clinical information overload in urological cancer.
BJU Int
; 130(3): 291-300, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34846775
15.
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
Br J Clin Pharmacol
; 88(7): 3182-3192, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35029306
16.
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.
Future Oncol
; 18(21): 2585-2597, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35656777
17.
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?
Future Oncol
; 18(35): 3867-3874, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36226865
18.
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.
Future Oncol
; 18(1): 35-45, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636627
19.
Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.
Future Oncol
; 18(19): 2361-2371, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35416053
20.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(4): 525-537, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33721560